Blog
RSS FeedPosted by Michael Wonder on 22 Feb 2023
Ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement ...
Posted by Michael Wonder on 21 Feb 2023
Karyopharm and Menarini receive full marketing authorisation from the UK Medicines & Healthcare Products Regulatory Agency for Nexpovio (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
21 February 2023 - Based on results from Phase 3 BOSTON study, marketing authorisation expands multiple myeloma indication. ...
Posted by Michael Wonder on 21 Feb 2023
NICE recommends 3 treatments for COVID-19 in final draft guidance
21 February 2023 - Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and ...
Posted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 21 Feb 2023
Rimegepant sulphate for the treatment or prevention of migraine
21 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of rimegepant ...
Posted by Michael Wonder on 20 Feb 2023
ABPI response to Lord O'Shaughnessy review
20 February 2023 - The Office for Life Sciences has today announced that Lord James O’Shaughnessy will conduct a review ...
Posted by Michael Wonder on 20 Feb 2023
Azafaros receives additional regulatory designations for AZ-3102 from FDA, EMA and MHRA
20 February 2023 - Azafaros today announced its progress in on-going interactions with health authorities regarding its lead asset, AZ-3102. ...
Posted by Michael Wonder on 17 Feb 2023
UK’s most expensive drug Libmeldy saved Teddi Shaw, but is too late for her sister
16 February 2023 - A toddler with a rare inherited condition has become the first child to be treated by ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 17 Feb 2023
Mitapivat sulphate for the treatment of patients with pyruvate kinase deficiency
16 February 2023 - NICE is unable to make a recommendation on the the use of mitapivat sulphate (Pyrukynd) for the ...
Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 ...
Posted by Michael Wonder on 16 Feb 2023
Living health technology assessments: how close to living reality?
16 February 2023 - HTA processes have remained largely unchanged, but innovative study designs (eg, pragmatic and adaptive clinical trials, single-arm ...
Posted by Michael Wonder on 16 Feb 2023
Tixagevimab and cilgavimab for the the prevention of COVID-19 disease
16 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Feb 2023
Vutrisiran for the treatment of patients with hereditary transthyretin-related amyloidosis
15 February 2023 - NICE has published final draft guidance on the use of vutrisiran for the treatment of adults ...
Posted by Michael Wonder on 14 Feb 2023
Verve Therapeutics announces VERVE-101 awarded Innovation Passport by the UK MHRA for the treatment of heterozygous familial hypercholesterolaemia
14 February 2023 - Verve Therapeutics today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of ...